Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $8.07 million. The enterprise value is $5.20 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 2.53 million shares outstanding. The number of shares has increased by 10.09% in one year.
| Current Share Class | 2.53M |
| Shares Outstanding | 2.53M |
| Shares Change (YoY) | +10.09% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 23.45% |
| Owned by Institutions (%) | 15.28% |
| Float | 1.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.05 |
| Forward PS | n/a |
| PB Ratio | 0.98 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 26.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.07
| Current Ratio | 5.07 |
| Quick Ratio | 4.17 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.13% and return on invested capital (ROIC) is -35.15%.
| Return on Equity (ROE) | -50.13% |
| Return on Assets (ROA) | -30.72% |
| Return on Capital (ROIC) | -35.15% |
| Revenue Per Employee | $194,000 |
| Profits Per Employee | -$5.28M |
| Employee Count | 1 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.31% in the last 52 weeks. The beta is 1.82, so CYCN's price volatility has been higher than the market average.
| Beta (5Y) | 1.82 |
| 52-Week Price Change | -28.31% |
| 50-Day Moving Average | 2.76 |
| 200-Day Moving Average | 2.87 |
| Relative Strength Index (RSI) | 50.98 |
| Average Volume (20 Days) | 9,095,569 |
Short Selling Information
The latest short interest is 747,855, so 29.55% of the outstanding shares have been sold short.
| Short Interest | 747,855 |
| Short Previous Month | 5,503 |
| Short % of Shares Out | 29.55% |
| Short % of Float | 46.65% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
In the last 12 months, CYCN had revenue of $194,000 and -$5.28 million in losses. Loss per share was -$2.12.
| Revenue | 194,000 |
| Gross Profit | -1.12M |
| Operating Income | -5.93M |
| Pretax Income | 3.01M |
| Net Income | -5.28M |
| EBITDA | n/a |
| EBIT | -5.93M |
| Loss Per Share | -$2.12 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 2.87M |
| Total Debt | n/a |
| Net Cash | 2.87M |
| Net Cash Per Share | $1.13 |
| Equity (Book Value) | 8.20M |
| Book Value Per Share | 3.24 |
| Working Capital | 2.85M |
Full Balance SheetCash Flow
| Operating Cash Flow | -6.23M |
| Capital Expenditures | n/a |
| Free Cash Flow | -6.23M |
| FCF Per Share | -$2.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -3,054.12% |
| Pretax Margin | -2,722.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |